Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ChiCTR2600125232) titled 'A single-arm intervention clinical study of apalolitovolrelimab combined with bevacizumab and HAIC in the first-line treatment of advanced hepatocellular carcinoma' on May 22.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine
Condition:
Advanced hepatocellular carcinoma
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-05-25
Target Sample Size: Experimental Group:46;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=308435
Published by ...